Functional activation of the estrogen receptor-α and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole.
Approximately 25% of breast cancers do not express the estrogen receptor-α (ERα) and consequently do not respond to endocrine therapy. In these tumors, ERα repression is often due to epigenetic modifications such as methylation and histone deacetylation. For this reason, we investigated the ability of the histone deacetylase inhibitor entinostat (ENT) to trigger reexpression of ERα and aromatase in breast cancer cells, with the notion that this treatment would restore sensitivity to the aromatase inhibitor (AI) letrozole. ENT treatment of tumor cells increased expression of ERα and aromatase, along with the enzymatic activity of aromatase, in a dose-dependent manner both in vitro and in vivo. Notably, ERα and aromatase upregulation resulted in sensitization of breast cancer cells to estrogen and letrozole. Tumor growth rate was significantly lower in tumor xenografts following treatment with ENT alone and in combination with letrozole than in control tumors (P > 0.001). ENT plus letrozole also prevented lung colonization and growth of tumor cells, with a significant reduction (P > 0.03) in both visible and microscopic foci. Our results show that ENT treatment can be used to restore the letrozole responsiveness of ER-negative tumors. More generally, they provide a strong rationale for immediate clinical evaluation of combinations of histone deacetylase and aromatase inhibitors to treat ER-negative and endocrine-resistant breast cancers.
Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine and University of Maryland Greenebaum Cancer Center, Baltimore, Maryland 21201, USA.
Gauri J
GJ
Sabnis
Olga
O
Goloubeva
Saranya
S
Chumsri
Nguyen
N
Nguyen
Saraswati
S
Sukumar
Angela M H
AM
Brodie
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001141:Aromatase / Q000096:biosynthesis* / Q000187:drug effects; D001549:Benzamides / Q000494:pharmacology*; D015153:Blotting, Western; D047628:Estrogen Receptor alpha / Q000096:biosynthesis* / Q000187:drug effects; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D000077289:Letrozole; D051379:Mice; D008819:Mice, Nude; D009570:Nitriles / Q000494:pharmacology*; D020411:Oligonucleotide Array Sequence Analysis; D011725:Pyridines / Q000494:pharmacology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014230:Triazoles / Q000494:pharmacology*; D015854:Up-Regulation; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D001549:Benzamides; D047628:Estrogen Receptor alpha; D009570:Nitriles; D011725:Pyridines; D014230:Triazoles; C118739:entinostat; D000077289:Letrozole; D001141:Aromatase
J Biol Chem. 2005 Jul 22;280(29):26729-34
15937340
Clin Cancer Res. 2004 Nov 1;10(21):7375-81
15534114
Cancer Res. 2005 May 1;65(9):3903-10
15867390
Blood. 2004 Apr 15;103(8):2892-9
15070660
J Steroid Biochem Mol Biol. 1998 Nov;67(4):293-304
9883986
Cancer Res. 2005 Jun 15;65(12):5380-9
15958587
Clin Breast Cancer. 2008 Oct;8(5):411-7
18952554
Cancer Res. 2000 Dec 15;60(24):6890-4
11156387
Nature. 2007 May 24;447(7143):433-40
17522677
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11032-7
20534486
Clin Cancer Res. 2007 May 1;13(9):2751-7
17473209
Breast Cancer Res Treat. 1998 Jul;50(1):63-71
9802621
Mol Endocrinol. 2005 Jul;19(7):1740-51
15746193
N Engl J Med. 2005 Dec 29;353(26):2807-9
16382068
Clin Cancer Res. 2002 Jul;8(7):2378-88
12114443
Cancer Res. 2006 Jun 15;66(12):6370-8
16778215
Oncologist. 2006 Jan;11(1):1-8
16401708
Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1235-6
19933447
Cancer Res. 2008 Jun 15;68(12):4518-24
18559495
Cancer Res. 2001 Oct 1;61(19):7025-9
11585728
Breast Cancer Res Treat. 1998;49 Suppl 1:S23-6; discussion S33-7
9797014
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7
17875771
Mol Cell. 2005 May 27;18(5):601-7
15916966
Crit Rev Toxicol. 2002;32(6):445-520
12487363
Clin Cancer Res. 2004 Aug 15;10(16):5375-80
15328175
J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7
17942301
Clin Cancer Res. 2007 Aug 15;13(16):4882-90
17699868
Cancer Res. 2001 Aug 1;61(15):5771-7
11479214
Cancer Res. 1993 Aug 1;53(15):3472-4
8339250
Mol Cancer Ther. 2010 Jan;9(1):46-56
20053764
J Mammary Gland Biol Neoplasia. 2010 Mar;15(1):35-47
20101445
Mol Endocrinol. 2005 Aug;19(8):2006-19
15774498
Int J Cancer. 2003 Nov 10;107(3):353-8
14506733
Cancer Res. 2009 Feb 15;69(4):1416-28
19190349
Clin Cancer Res. 2008 Jul 15;14(14):4517-25
18579665
Cancer Res. 1994 May 15;54(10):2552-5
8168078